Summary
Hematology and oncology sits within a rising global cancer burden. The latest available estimates report 20.6 million new cancer cases and 9.8 million cancer deaths worldwide 1. Hematologic cancers are not separately ranked in that analysis, but leukemia alone accounts for 487,294 new cases 3. In the United States, projected demand for oncologists and radiation oncologists is forecast to grow 40%, against a 25% supply increase 7. Access to radiotherapy and trained professionals is sharply unequal between high-income and low-income countries [S10, S11]. Cancer medicine spending reached $252 billion at list prices, with a forecast of $441 billion 9. Cell therapy adds a major cost pressure, with a median CAR-T product cost of $402,500 in one US study 12. The pack lacks hematology-specific service volumes, waiting times and public, private and community comparisons, so the conclusions are directional.
Key findings
-
1
The cancer burden is large and rising
The latest available global estimates report 20.6 million new cancer cases and 9.8 million deaths, a scale that places continuing pressure on hematology and oncology services.
Confidence: High -
2
Projected case growth is substantial but is a forecast
Current trends are projected to reach 34 million new cases a year and 17.5 million deaths. This is a projection, not an observed figure.
Confidence: Medium -
3
US oncology demand is projected to outpace supply
Demand for oncologists and radiation oncologists is projected to grow 40%, against a 25% supply increase. The training pipeline grew faster in positions than in applicants, but the pack does not show that this closes the gap.
Confidence: Medium -
4
Radiotherapy access is highly unequal
Within 120 minutes, 93.1% of high-income country populations have radiotherapy access, compared with 17.1% in low-income countries.
Confidence: High -
5
Drug price dominates CAR-T cost, and cost-effectiveness is uncertain
Drug price represents 75% of total CAR-T cost across reviewed studies, and cost-effectiveness depends on patient characteristics, cancer type and model assumptions.
Confidence: Medium -
6
Spending is large, but the basis of the figure matters
Cancer medicine spending at list prices is $252 billion and is forecast to reach $441 billion. The figure covers all oncology medicines and does not isolate hematology.
Confidence: Medium
1Industry definition and scope
This report covers hematology and oncology as a specialty that diagnoses and treats blood cancers, including leukemia, lymphoma and myeloma, along with other cancers managed by medical and hematology oncologists 5. The global cancer estimates cover 34 cancers in 186 countries and do not rank hematologic cancers separately 1. Hematologic data are therefore reported where the pack provides them, mainly for leukemia and lymphoma, and are not forced into overall cancer totals.
Geographic scope is global, with US-specific data for the workforce, the training pipeline and CAR-T costs. The reporting period is the latest available data. Several sources are undated in their extracts, including the radiotherapy figures from the IAEA 10, the radiotherapy access study 11, the CAR-T cost studies [S12, S13] and the low-income country oncology workforce figures 14. Those figures are reported as current, but their periods could not be confirmed.
Terminology matters. Incidence counts new cases, prevalence counts people living with a disease, and age-standardized rates adjust for differences in population age [S3, S4]. Spending can be stated at list price or net price, and the two are not interchangeable 9. Radiotherapy is included because it is part of oncology care, although it is not specific to blood cancers. Vendor market-research estimates were excluded as primary figures.
The analysis is at industry and system level. It does not assess individual treatment choices, and nothing here is individual medical, legal, investment or engineering advice.
2Market size, structure and value chain
Cancer medicine spending is the clearest market-size measure in the pack. IQVIA reports cancer medicine spending at list prices of $252 billion globally in the latest available period, with a forecast of $441 billion and average annual growth of 11.9% over the recent multi-year period 9. These figures cover all oncology medicines, not hematology alone, so they indicate the scale of the wider market rather than the hematology share. The pack contains no verified hematology-specific share of drug spending.
The basis of the spending figure matters. The list-price figure is not the same as a net-style estimate, and the pack notes a lower net-style figure that was not reconciled with the list-price figure 9. Vendor market reports in the pack give wide ranges for oncology market size. They are treated as vendor estimates and are not cited here as primary figures.
The value chain runs from drug and cell therapy developers and manufacturers, through specialist hospitals, clinics and radiotherapy centers, to payers and patients. Each stage has its own constraint. Radiotherapy depends on equipment, with one machine serving on average 140,000 people in high-income countries against over 15 million in low-income countries 10. Clinical capacity depends on trained staff, and more than 90% of trained cancer professionals are concentrated in higher-income countries 10.
Revenue models are described in the pack mainly through product pricing. For CAR-T therapy, drug price represents 75% of total cost across reviewed studies, with a mean drug cost of $391,060 13. The pack therefore points to product acquisition as the dominant cost layer, but it does not show how payers and providers divide that value.
- Cancer medicine spending at list prices 252US$ billion Observed Worldwide, Latest available data [9]
- Forecast cancer medicine spending at list prices 441US$ billion Forecast Worldwide, Future period cited by source [9]
- Average annual growth in oncology medicine spending 11.9percent per year Observed Worldwide, Recent multi-year period [9]
Spending figures are list-price figures. The pack notes an unreconciled lower net-style estimate, so the list-price basis is stated explicitly.
Assumptions behind these figures
- Spending figures cover all oncology medicines and are not specific to hematology.
3Customers, demand and adoption
Demand is driven by disease burden. The latest available estimates put global new cancer cases at 20.6 million and deaths at 9.8 million 1. Projections at current trends reach 34 million new cases a year and 17.5 million deaths, but these are forecasts, not observations 2. Leukemia alone is reported at 487,294 new cases and 305,405 deaths 3.
In the United States, an estimated 192,070 people were expected to be diagnosed with leukemia, lymphoma or myeloma, and an estimated 176,980 people were living with or in remission from myeloma 5. Both are forecasts from an industry association. Non-Hodgkin lymphoma had the highest age-standardized incidence among the blood cancers reported, at 12.54 per 100,000 3.
Access is the main unmet need in the pack. About half of cancer patients need radiotherapy, but in low-income countries as few as one in ten people with cancer have access 10. Within 120 minutes of travel, 76.3% of the global population has radiotherapy access, compared with 17.1% in low-income countries and 93.1% in high-income countries 11. The chart shows the gap.
Patient purchasing criteria in the pack are mainly financial. In one US CAR-T study, the median out-of-pocket copayment was $510 against a median product cost of $402,500 12. A secondhand report of widespread financial toxicity was not confirmed against its original paper and is not relied on here. Changing expectations, patient preferences and digital engagement are not covered by any verified source in the pack.
- Estimated new leukemia, lymphoma or myeloma diagnoses 192,070people Forecast United States, Latest available estimate [5]
- Global radiotherapy access within 120 minutes 76.3percent of population Observed Worldwide, Latest available data [11]
Demand figures mix observed estimates and forecasts. Forecasts are labelled as such in the text.
4Competitive landscape and key players
The pack does not provide market share, revenue or company-level data for hematology or oncology providers. Comparable company examples are therefore limited, and this section compares provider types and information organizations rather than commercial companies.
The pack does not verify a public, private or community comparison of hematology-oncology revenue, volumes or outcomes. The closest proxy is workforce location: only 4% of medical and hematology oncologists work in counties with high cancer mortality rates 6. This points to concentration of specialist capacity where mortality is lower, but the pack does not separate public, private or community practices.
Organizations named in the pack play different roles. ASCO publishes US workforce analysis 6. IARC, through GLOBOCAN, publishes global incidence and mortality estimates 1. The IAEA reports on radiotherapy access and machine ratios 10. Blood Cancer United publishes blood cancer statistics as an industry association 5. Targeted Oncology reports workforce analysis drawn from other data sources 7. These are information providers rather than competing suppliers, so they are not ranked against each other.
Competitive pressure appears in two places: CAR-T pricing, where drug price is the dominant cost 13, and workforce competition, where demand is projected to outpace supply 7. Concentration of trained professionals is highest in higher-income countries 10.
| Indicator | Reported figure | Reading |
|---|---|---|
| Patients needing radiotherapy | About half of cancer patients | Need is high across settings |
| Patients with access in low-income countries | As few as 1 in 10 | Access is very limited |
| People per radiotherapy machine | About 140,000 in high-income countries; over 15 million in low-income countries | Capacity differs by a very large factor |
| Share of trained cancer professionals in higher-income countries | More than 90% | Workforce is concentrated |
Provider comparison is limited to information organizations and workforce location. No provider-type revenue or outcome comparison was verified.
5Technology, operations and workforce
The US workforce is the most detailed evidence in the pack. As of January of the latest available period there were 27,475 oncologists, about 43% of whom specialize in hematology and oncology 7. Projected demand is forecast to grow 40%, against a 25% increase in supply 7. ASCO reports that coverage of medical and hematology oncologists is at risk for 68% of the US population aged 55 and older 6.
Training pipelines are growing, but this does not show that supply will meet projected demand. Annual hematology and oncology training positions rose 66% over the reported period, while applicants rose 34% 8. Positions are growing faster than applicants, but the training data and the workforce forecast come from different sources and periods, so they cannot be combined into a single supply estimate [S7, S8].
Technology in the pack centers on therapy and equipment. CAR-T therapy is documented in cost studies for relapsed or refractory B-cell lymphomas 12 and for blood cancers more broadly 13. Its cost-effectiveness is uncertain and depends on patient characteristics, cancer type and model assumptions 13. Radiotherapy is established at scale but unevenly distributed 10. In this report, CAR-T is treated as an established but high-cost option whose value is still debated, not as a proven standard for all patients.
Digital health, productivity gains and automation are not covered by any verified source in the pack, so no assessment is made. Staffing capacity is the clearest operational constraint in the evidence.
- Oncologists in the United States 27,475oncologists Observed United States, January of the latest available period [7]
- Projected growth in oncologist and radiation oncologist demand 40percent Forecast United States, Projected period cited by source [7]
- Growth in annual hematology and oncology training positions 66percent Observed United States, Reported training period [8]
Workforce projections and training data come from different sources and periods. They are reported side by side, not merged.
6Regulation, standards, risk and sustainability
The pack does not contain a regulator's rule, a standards document or a voluntary guidance text for hematology or oncology. The only jurisdiction referenced is the United States, where cost and coverage are discussed, but the pack states that CMS coverage details were not verified. Binding requirements, proposed rules and voluntary guidance therefore cannot be distinguished from the sources, and this section does not identify them.
Safety and quality expectations cannot be assessed against a verified standard. The pack reports no current hematology-specific outcome data by subtype, so it cannot show whether outcomes meet expectations. For CAR-T, evidence standards are reflected in uncertain cost-effectiveness rather than in a clear threshold 13.
Privacy and ethics: the report uses only population and aggregate figures. No individual patient data appear. Population estimates are not guidance for any person's treatment, and clinical decisions require a qualified clinician.
Financial and operational risks are documented: high product costs [S12, S13], workforce coverage risk 6 and uneven radiotherapy access 11. Environmental and sustainability factors, including manufacturing and energy use, are not covered by any verified source and are not assessed.
7Challenges, opportunities and case examples
The main constraints are workforce shortage, unequal access and high cell therapy prices. The gap between income groups is stark: as few as 0.09 oncologists per 100,000 people in low-income countries, against a median of 1.6 in high-income countries 14, and only 10% of the world's teletherapy machines are available in low- and middle-income countries 14.
Opportunities include a growing training pipeline 8 and better placement of radiotherapy facilities. A geospatial study frames facility placement as a way to reduce access disparities 11. Emerging CAR-T use and cost reduction are areas to monitor, but the pack does not show that prices are falling.
Case example one is CAR-T care costs in the United States. A study of care during CAR-T for relapsed or refractory B-cell lymphomas found a median product cost of $402,500 and a median out-of-pocket copayment of $510, with product acquisition driving most care costs 12. This is one study, and its period is not stated in the extract.
Case example two is the US workforce response. ASCO's workforce analysis 6 and the training-position data 8 show how the specialty is responding to projected shortages, but the outcome is not yet observed. Case example three is global inequality in access, described by the IAEA 10 and IARC 2. Named commercial companies do not appear in the pack, so company-level examples are not available.
8Outlook and strategic implications
Near term, demand from rising incidence is likely to keep pressure on specialist capacity, based on forecasts in the pack [S2, S7]. Medium term, if current trends continue, spending on oncology medicines could approach $441 billion, but this is a list-price projection 9 and may not reflect net prices paid.
Key uncertainties include the cost-effectiveness of CAR-T 13, whether training growth will match demand [S7, S8], and whether access gaps narrow or widen depending on facility placement and workforce investment [S10, S11]. The evidence does not allow a confident forecast of any of these.
Practical implications: providers should plan workforce capacity against forecasts and treat training growth as one input rather than a solution. Payers and policymakers should note that drug price dominates cell therapy cost 13. Manufacturers and funders may track access gaps in low-income countries 14. Researchers should prioritize the missing data: hematology service volumes, waiting times, subtype outcomes and public, private and community comparisons.
9Conclusion
The most defensible conclusion is that demand for hematology and oncology care is growing faster than specialist supply in the United States, that radiotherapy and trained staff are highly unequal globally, and that cell therapy costs are a major pressure [S7, S10, S13]. Hematology-specific volume, waiting-time and outcome data are missing, so these conclusions are directional.
How this was built
The report uses only the verified source pack. Figures are labelled as observed, estimated or forecast as the sources state. Vendor estimates were excluded as primary figures. Where the pack gives no hematology-specific data, the gap is stated rather than filled. Several source extracts are undated, and their periods could not be confirmed. Some source URLs are shortened to the publisher domain because the full address contains year-like digits.
Limits to keep in mind
- No hematology-specific service volumes (chemotherapy, transplant or apheresis procedures) were available.
- No verified waiting-time data for hematology or oncology clinics were available in any country.
- No hematology-specific share of global cancer drug spending was available, because IQVIA figures cover all oncology medicines.
- The list-price spending figure and a lower net-style estimate were not reconciled, so the basis of each figure must be stated.
- Vendor market-research estimates were excluded as primary figures because they conflict widely and are not verified.
- No verified comparison of public, private and community hematology-oncology providers was available for revenue, volumes or outcomes.
Sources
-
1
Global cancer statistics: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries
acsjournals.onlinelibrary.wiley.com -
2
IARC releases GLOBOCAN: rising cancer burden exposes gaps in prevention and care
uicc.org -
3
Disease burden of hematological malignancies worldwide, in China and in the United States based on the GLOBOCAN and Global Burden of Disease data
pmc.ncbi.nlm.nih.gov -
4
Global burden of hematologic malignancies and evolution patterns over the past 30 years
ncbi.nlm.nih.gov -
5
Blood cancer facts and statistics
bloodcancerunited.org -
6
State of the Hematology and Medical Oncologist Workforce in America (ASCO press release)
asco.org -
7
The Shrinking Oncology Workforce and Its Impact on Supply and Demand
targetedonc.com -
8
Growth in Hematology/Oncology Training Positions Exceeds Growth in Applicants
cancertherapyadvisor.com -
9
Global Oncology Trends
iqvia.com -
10
Bridging the Global Gap in Cancer Care
iaea.org -
11
Global access to radiotherapy: A geospatial analysis of current disparities and optimal facility placement
sciencedirect.com -
12
Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas
ncbi.nlm.nih.gov -
13
Cost-effectiveness of CAR T-cell therapy for blood cancers: an updated systematic review
link.springer.com -
14
Global Oncology: Tackling Disparities and Promoting Innovations in Low- and Middle-Income Countries
ascopubs.org